Scott Smith - Celgene President - Inflammation & Immunology
President
Mr. Scott A. Smith serves as President, Chief Operating Officer of the Company. Prior thereto he was President, Global Inflammation Immunology since August 2014. Previously he was Senior Vice President, Global Head of I I. He joined Celgene in 2008 as Vice President, Global Marketing Inflammation and Immunology. From 2003 to 2008, Mr. Smith was with Biovail, holding positions of General Manager Biovail U.S., General Manager Biovail Canada and Global Commercial Head. As Global Commercial Head for Biovail, he was responsible for global revenue generation, global commercial strategies, business development strategy, and input into global regulatory and clinical development strategies. Prior to Biovail, Mr. Smith was with PharmaciaUpjohn for 16 years where he held various positions including Vice President U.S. Sales, Vice President Marketing Europe based in Paris, Vice President and Commercial Lead for Canada based in Toronto, and Commercial and Regulatory Head for South East Asia based in Hong Kong. Mr. Smith holds a BSc in Chemistry and an HBSc in Pharmacology and Toxicology from the University of Western Ontario and a Masters of International Business Management from the American Graduate School of International Management . Mr. Smith became a member of the Board of Directors of Titan Pharmaceuticals on January 1, 2017. since 2017.
Age | 54 |
Tenure | 7 years |
Phone | 908 673-9000 |
Web | www.celgene.com |
Scott Smith Latest Insider Activity
Tracking and analyzing the buying and selling activities of Scott Smith against Celgene stock is an integral part of due diligence when investing in Celgene. Scott Smith insider activity provides valuable insight into whether Celgene is net buyers or sellers over its current business cycle. Note, Celgene insiders must abide by specific rules, including filing SEC forms every time they buy or sell Celgene'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Scott Smith over six months ago Payment of 1791 shares by Scott Smith of BioatlaInc subject to Rule 16b-3 | ||
Scott Smith over six months ago Payment of 1791 shares by Scott Smith of BioatlaInc subject to Rule 16b-3 | ||
Scott Smith over six months ago Acquisition by Scott Smith of 50000 shares of BioatlaInc subject to Rule 16b-3 | ||
Scott Smith over six months ago Payment of 1791 shares by Scott Smith of BioatlaInc subject to Rule 16b-3 |
Celgene Management Efficiency
The company has return on total asset (ROA) of 0.14 % which means that it generated a profit of $0.14 on every $100 spent on assets. This is way below average. Celgene's management efficiency ratios could be used to measure how well Celgene manages its routine affairs as well as how well it operates its assets and liabilities.The company currently holds 20.1 B in liabilities with Debt to Equity (D/E) ratio of 199.9, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Celgene has a current ratio of 3.37, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Celgene until it has trouble settling it off, either with new capital or with free cash flow. So, Celgene's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Celgene sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Celgene to invest in growth at high rates of return. When we think about Celgene's use of debt, we should always consider it together with cash and equity.
Similar Executives
Showing other executives | PRESIDENT Age | ||
Steven Bradford | HNI Corp | 66 | |
Kris Yates | HNI Corp | N/A | |
Mark Anderson | Acco Brands | 62 | |
Scott Buchholz | Black Hills | 58 | |
Lawrence Ricketts | One Liberty Properties | 47 | |
Israel Rosenzweig | One Liberty Properties | 77 | |
Donna Meade | HNI Corp | 55 | |
Brian Iverson | Black Hills | 61 | |
Jeffrey Gould | One Liberty Properties | 58 | |
Erik Keller | Black Hills | 60 | |
Vincent Berger | HNI Corp | 51 | |
Natalie Teear | Hudson Pacific Properties | N/A | |
Jason Hagedorn | HNI Corp | 50 | |
Thomas Tedford | Acco Brands | 53 | |
Patrick Buchenroth | Acco Brands | 57 | |
David Kalish | One Liberty Properties | 77 | |
B Bullock | HNI Corp | 43 | |
Marshall Bridges | HNI Corp | 54 | |
Kimberly Nooney | Black Hills | 52 | |
Christopher Barton | Hudson Pacific Properties | 54 | |
Neil McLachlan | Acco Brands | 57 |
Management Performance
Return On Equity | 1.0E-4 | |||
Return On Asset | 0.14 |
Celgene Leadership Team
Elected by the shareholders, the Celgene's board of directors comprises two types of representatives: Celgene inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Celgene. The board's role is to monitor Celgene's management team and ensure that shareholders' interests are well served. Celgene's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Celgene's outside directors are responsible for providing unbiased perspectives on the board's policies.
James Loughlin, Independent Director | ||
Michael Friedman, Independent Director | ||
Michael Bonney, Director | ||
Hans Bishop, Director | ||
John Weiland, Director | ||
Gerald Masoudi, Executive Vice President General Counsel and Corporate Secretary | ||
Gilla Kaplan, Independent Director | ||
Patricia Hall, Director | ||
Robert Hugin, Chairman of the Board and Presidentident, CEO | ||
Peter Kellogg, CFO, Executive Vice President | ||
David Elkins, Executive Vice President | ||
Perry Karsen, CEO of Celgene Cellular Therapeutics | ||
Rupert Vessey, President - Research and Early Development | ||
Carrie Cox, Independent Director | ||
Terrie Curran, President Global Inflammation & Immunology Franchise | ||
Michael Pehl, President Hematology & Oncology | ||
Mark Alles, President, COO and Director | ||
Alise Reicin, President - Global Clinical Development | ||
Jonathan Biller, Executive Vice President General Counsel | ||
Julia Haller, Director | ||
Robert Hershberg, Chief Scientific Officer | ||
Jacqualyn Fouse, President of Global Hematology and Oncology and Director | ||
Ernest Mario, Independent Director | ||
Scott Smith, President - Inflammation & Immunology | ||
Thomas Daniel, Executive Vice President and Presidentident - Research and Early Development | ||
Richard Barker, Independent Director | ||
Michael Casey, Lead Independent Director |
Celgene Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Celgene a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | 1.0E-4 | |||
Return On Asset | 0.14 | |||
Profit Margin | 0.30 % | |||
Operating Margin | 51.47 % | |||
Current Valuation | 85.34 B | |||
Shares Outstanding | 708.74 M | |||
Shares Owned By Insiders | 0.22 % | |||
Shares Owned By Institutions | 77.62 % | |||
Number Of Shares Shorted | 12.95 M | |||
Price To Earning | 13.31 X |
Pair Trading with Celgene
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Celgene position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Celgene will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to Newell Brands could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Newell Brands when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Newell Brands - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Newell Brands to buy it.
The correlation of Newell Brands is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Newell Brands moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Newell Brands moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Newell Brands can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Idea Optimizer module to use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio .
Other Consideration for investing in Celgene Stock
If you are still planning to invest in Celgene check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Celgene's history and understand the potential risks before investing.
Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
Equity Valuation Check real value of public entities based on technical and fundamental data | |
Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
Share Portfolio Track or share privately all of your investments from the convenience of any device | |
ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk |